top of page
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Search
Mar 19, 20234 min read
Kadimastem Earns FDA IND Approval For its US Phase IIa Clinical Trial with AstroRx® to Treat ALS
IND Approval Allows Commencement of the Multi-Site Clinical Trial and Recruitment of Eligible ALS Patients for Repeated Dosing of...
Feb 19, 20235 min read
Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for ALS
The study will Determine if Repeated Dosing of AstroRx® in Three-month Intervals Achieves a Continuous Delay of the Progression of ALS to...
Feb 15, 20234 min read
Kadimastem's Clinical Trial in ALS Patients was Publicized in the Journal of Translational Medicine
The publication presents the company’s successful phase I/IIa clinical trial in Israel to evaluate the safety, tolerability, and...
Feb 5, 20234 min read
Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening
It’s in addition to the company's patents for the product in the US, Europe, Japan and Israel. The patent grant strengthens the company's...
Jan 9, 20233 min read
Kadimastem Announces it raised appx 7.5 million NIS by rights offering
The company's main stakeholders, Prof. Michel Revel and Mr. Julian Ruggeri and the European Alpha Capital Anstalt, expressed confidence...
Dec 20, 20225 min read
Kadimastem and iTolerance’s Proposed Collaboration With Receipt of US $1 Million BIRD Grant
Kadimastem and iTolerance’s Proposed Collaboration to Develop a Potential Cure for Diabetes is Further Strengthened With Receipt of NIS...
Sep 28, 20224 min read
Kadimastem Receives Approval of Patent registration Used to Develop IsletRx for Diabetes
Cell Selection and Enrichment Technology is Used to Develop IsletRx Treatment for Diabetes in a Third Territory This approval of...
Aug 9, 20224 min read
Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment
The patent supports the Phase IIa study of AstroRx® for ALS planned to begin in the US in 2023 Ness Ziona, Israel, August 9, 2022 ---...
Jun 8, 20224 min read
Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement
The Evaluation Agreement is Towards the Potential Licensing of “Immune Evasive” Cells If the feasibility study is successful, it would be...
May 30, 20223 min read
Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening
Ness Ziona, Israel, May 30, 2022 --- Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS,...
May 17, 20224 min read
Kadimastem Expands R&D Program to Include Multiple Sclerosis
Following positive results from its first clinical study in ALS, Kadimastem Tests The Potential of AstroRx® As A Therapeutic Treatment...
Mar 3, 20223 min read
Kadimastem Receives Grant for a Total Budget of $3.1 million from the Israeli Innovation Authority
The Grant will support the Further Development of Cell Therapy Product AstroRx®, for the Treatment of ALS And support the Company’s FDA...
Dec 13, 20214 min read
Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority
For the Support of Production Scale Up of Astrocyte cells Used to Produce ALS Cell Therapy Treatment AstroRx® in Preparation for Phase...
Nov 25, 20215 min read
ILEX Medical to Invest 10 million NIS ($3.2 million)
ILEX Medical receives options that if exercised would increase this financing round to 21 million NIS ($6.7 million) Kadimastem's Board...
Nov 15, 20211 min read
We rang the TASE bell today!
In honor of the “International Diabetes Awareness Day” and the 100-year anniversary of the discovery of insulin, Kadimastem opened the...
Oct 25, 20214 min read
Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement
The raise was led by Clover Wolf, Alpha Capital Anstalt and the controlling shareholders of the company, Professor Michel Revel and Mr....
Oct 12, 20213 min read
Successful Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes
Kadimastem Holds Successful Preliminary Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes NESS ZIONA,...
Jul 21, 20213 min read
Patent for Cell Selection of Beta Cells to Treat and Potentially Cure Diabetes was Granted in Japan
Ness Ziona, Israel, July, 2021 --- Cell therapy company Kadimastem Ltd (TASE: KDST) has received its patent approval from the Japanese...
May 11, 20213 min read
Kadimastem Announces Publication in Frontiers in Endocrinology of a Peer-Reviewed Article
Demonstrating Advancement in the Company’s Technology to Treat Diabetes Ness Ziona, Israel, May 11th, 2021, Kadimastem (TASE: KDST), a...
Apr 26, 20213 min read
Kadimastem Raises NIS 22.3 Million ($6.8 Million)
Total Potential of NIS 53.4 Million ($16 Million) with Warrants in a Private Placement Institutional investors Alpha Capital Anstalt and...
bottom of page